Clinical Trials Browser

PIK3CA-Mutated Cancers × 30 days × Clear all

NCT06496568 2026-05-27

A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers

Phase 1 Active not recruiting

PIK3CA-Mutated Cancers